Literature DB >> 3243737

Activity of cilofungin (LY121019) against Candida species in vitro.

F C Odds1.   

Abstract

Cilofungin (LY121019) was compared with amphotericin B in vitro for its inhibitory and fungicidal activity against Candida species. In minimal inhibitory concentration (MIC) tests the two compounds showed comparable inhibitory activity against 31 isolates of C. albicans and C. tropicalis. However, cilofungin was by comparison only weakly active against 19 isolates representing the species C. glabrata, C. kefyr and C. krusei, and essentially inactive against 11 isolates representing C. guilliermondii and C. parapsilosis. The inhibitory activity of cilofungin, unlike that of amphotericin B, was reduced in medium containing serum. Relative inhibition factors (RIFs) for the two compounds confirmed the MIC data: RIFs of 85% and more were obtained in tests with species other than C. albicans and C. tropicalis: for the latter two species, RIFs were in the range 41-66%, indicating drug activity comparable to that of systematically active azole compounds. (RIFs for amphotericin B were less than 40% for all isolates.) Cilofungin was generally less fungicidal than amphotericin B, and it was only rarely fungicidal in tests done in medium containing serum. Because of its inhibitory action and its low toxicity, the compound may prove to be therapeutically useful in infections caused by the two most commonly encountered pathogenic Candida species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243737     DOI: 10.1093/jac/22.6.891

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Ribosomal protein S6 phosphorylation is controlled by TOR and modulated by PKA in Candida albicans.

Authors:  Tahmeena Chowdhury; Julia R Köhler
Journal:  Mol Microbiol       Date:  2015-08-22       Impact factor: 3.501

2.  Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.

Authors:  K R Smith; K M Lank; C G Cobbs; G A Cloud; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

3.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

5.  In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.

Authors:  K R Smith; K M Lank; W E Dismukes; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

6.  Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence for enhanced activity with combination therapy.

Authors:  A M Sugar; L Z Goldani; M Picard
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity.

Authors:  E Anaissie; R Hachem; C K-Tin-U; L C Stephens; G P Bodey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  The adherence of Candida albicans to acrylic resin reinforced with different fibers.

Authors:  Lale Karaagaclioglu; Gulsen Can; Burak Yilmaz; Nilgun Ayhan; Olcay Semiz; Hakan Levent
Journal:  J Mater Sci Mater Med       Date:  2007-08-01       Impact factor: 3.896

9.  Characterization of mucosal Candida albicans biofilms.

Authors:  Anna Dongari-Bagtzoglou; Helena Kashleva; Prabhat Dwivedi; Patricia Diaz; John Vasilakos
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

Review 10.  Innocent until proven guilty: mechanisms and roles of Streptococcus-Candida interactions in oral health and disease.

Authors:  H Xu; H F Jenkinson; A Dongari-Bagtzoglou
Journal:  Mol Oral Microbiol       Date:  2014-06       Impact factor: 3.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.